Ken Truitt is a physician-scientist with over 20 years in the pharmaceutical industry. He began his career at Merck & Co., Inc., designing and overseeing clinical trials of COX-2 inhibitors for the treatment of osteoarthritis and rheumatoid arthritis. Subsequently, he joined Sankyo Pharma Development, Inc., and played a key role in metabolic and immunomodulatory drug development. Continuing at Daiichi Sankyo, post-merger, Ken held several positions of increasing responsibility, including global head of translational medicine and clinical pharmacology, and therapeutic area head for internal medicine. His experience has spanned INDs through NDAs, and he has been a major contributor to drug approvals in areas of inflammation, pain, and type-2 diabetes mellitus, and of a direct Factor Xa inhibitor for prevention of venous thromboembolism and stroke.
Before joining industry, Ken was an instructor and assistant professor of internal medicine, in the rheumatology division at the University of California at San Francisco (UCSF). He conducted basic research on T-cell signaling through accessory and co-stimulatory receptor-mediated pathways. Ken completed a fellowship in rheumatology at UCSF and an internship and residency in internal medicine at Johns Hopkins University Hospital in Baltimore. He has a medical doctorate from the University of California at San Diego (UCSD), and a bachelor of science degree in chemistry from Stanford University.